Mechelen, Belgium; 18 December 2007 - Galapagos NV (Euronext & LSE: GLPG), an integrated drug discovery company, announces today that it has reached significant milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of EUR 7.5 million from GSK.
